99.00 0.00 (0.00%)
After hours: 4:43PM EDT
|Bid||98.70 x 800|
|Ask||99.62 x 1200|
|Day's Range||98.73 - 99.65|
|52 Week Range||76.41 - 99.65|
|PE Ratio (TTM)||42.69|
|Earnings Date||Nov 20, 2018|
|Forward Dividend & Yield||2.00 (2.06%)|
|1y Target Est||102.65|
Let's check out the Yahoo Finance charts of the day. Under Armour (UA): Shares are up in early trade, at around 2.7%. J.P. Morgan upgraded Under Armour stock to "neutral" from "underweight". The firm said it believed the athletic apparel maker will meet consensus earnings estimates for fiscal 2018-2019. American Airlines (AAL): Shares up here, 2.9%. The airline is the latest to raise their checked bag fee by $5 joining United Continental, Delta Airlines and Jet Blue. The first checked bag will be $30 and the second bag will be $40. Medtronic (MDT): Shares down here, around .24%. Medtronic has reached a deal to acquire medical device maker Mazor Robotics for about $1.64 billion in cash. The company is focused on strengthening its provision of technology for robotic-assisted spine surgeries. For more on today's big stock movers check out the Final Round, live at 3:30 p.m. ET, right here on Yahoo Finance.
The medical-device giant is pursuing the patent as companies and researchers nationwide angle to develop painless techniques for measuring and tracking glucose levels in diabetes patients. Medtronic's idea would change color based on glucose levels and could heat the skin for insufficiently sweaty patients.
Sensible investors years ago could have chosen market leaders like Polaroid, General Motors (NYSE:GM), Sears (NASDAQ:SHLD), and myriad other ‘safe’, seemingly dominant stocks that would go on to stumble badly — or even go bankrupt. It’s far from guaranteed, however, that even torrid growth will produce much in the way of long-term returns relative to the stocks’ current prices.
September 25, 2018 - Medtronic plc (MDT) today announced the U.S. launch of the Infinity(TM) Occipitocervical-Upper Thoracic (OCT) System designed to simplify posterior cervical spine surgery. The Infinity OCT System is a complete procedural solution that integrates navigation and biologics with Medtronic`s comprehensive devices and instrumentation to create efficiency in fusion procedure workflows for the upper back and neck. The announcement was made during the North American Spine Society meeting taking place from September 26th - 29th in Los Angeles where Medtronic is exhibiting at Booth #1201.
September 24, 2018 - Medtronic plc (MDT), a global leader in heart valve therapies, today announced new data presented at the 30th Transcatheter Cardiovascular Therapeutics (TCT) conference, the annual scientific symposium of the Cardiovascular Research Foundation. Over the weekend, investigators presented the longest-term data to-date from the CoreValve U.S. Pivotal Trial, in addition to the complete two-year outcomes from the SURTAVI trial, which confirmed the excellent outcomes previously predicted in aortic stenosis patients at intermediate surgical risk.
China stocks were early movers Friday, as McDonald's topped the Dow and Mazor Robotics spiked on takeover news. Micron Technology dragged chip stocks lower.
September 22, 2018 - Investigators today unveiled new clinical data from the physician-initiated BIONYX study, representing the first all-comers analysis in nearly 2,500 patients comparing the safety and efficacy of the durable polymer Resolute Onyx(TM) drug-eluting stent (DP-DES) from Medtronic plc (MDT) to the Orsiro biodegradable polymer stent (BP-DES). At one year, the study showed patients with coronary artery disease who were treated with Orsiro BP-DES received no clinical advantage compared to patients treated with the Resolute Onyx DP-DES, and Orsiro BP-DES demonstrated a higher rate of stent thrombosis.1 Published simultaneously in The Lancet, the results were presented today during a Late-Breaking Clinical Trial session at the 30th Transcatheter Cardiovascular Therapeutics conference (TCT), the annual scientific symposium of the Cardiovascular Research Foundation.
Investors who want to cash in on Medtronic plc’s (NYSE:MDT) upcoming dividend of US$0.50 per share have only 4 days left to buy the shares before its ex-dividend date, 27Read More...
It's that time again! "Mad Money" host Jim Cramer rang the lightning round bell, which means he gave his take on callers' favorite stocks at rapid speed. Notice how FedEx has come right back even though it was supposed to be such a disappointing quarter. ActionAlerts, my charitable trust, has others, but they may be too so-called go-go for you.
Jim Cramer zooms through his take on callers' favorite stocks, including a small independent energy play that he wouldn't recommend to investors.
On a mixed day for the major benchmarks, Medtronic announced plans to buy Mazor Robotics, and Micron Technology beat expectations for its latest quarter.
The deal will have Medtronic acquiring Mazor Robotics (OTCMKTS:MZRTF) for $1.64 billion. It will be doing this by purchasing all outstanding shares of Mazor Robotics stock for $58.50 per American Depository Share, or $29.25 per ordinary share. Medtronic says that it will be using cash to fund its acquisition of Mazor Robotics stock.
NEW YORK, Sept. 21, 2018-- The following statement is being issued by Levi & Korsinsky, LLP:. To: All Persons or Entities who purchased Mazor Robotics, Inc. stock prior to September 20, 2018. You are hereby ...
The consolidation will combine Medtronic's (MDT) spine implants, navigation and intra-operative imaging technology with Mazor Robotics' robotic-assisted surgery (RAS) systems.
Here are some of the companies with shares expected to trade actively in Friday’s session. Check back closer to the market open for an updated list. Micron Technology Inc.—Down 2.7%: The memory chip maker issued a disappointing forecast with its fiscal fourth-quarter report, expecting revenue for the quarter ending in November to grow by its slowest rate in two years.
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 20.) Abbott Laboratories (NYSE: ABT ) Acceleron ...
On September 13, Abbott Laboratories (ABT) announced its 379th consecutive quarterly dividend, which is payable on November 15. The dividend of $0.28 per share will be paid to shareholders of record as of the close of business on October 15. The company’s annual dividend in 2017 was $1.06, while its indicated annual dividend for 2018 is $1.12 per share. Last year, it paid a quarterly dividend of $0.265 to its shareholders, so its new quarterly dividend represents an increase of ~5.7%.
Sept 21 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1000 GMT on Friday: ** Adobe Systems Inc has agreed to buy Marketo Inc for $4.75 billion from private equity ...